|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Antagonist antibodies to PD-1 and BT-H1 (PD-L1) in the treatment of advanced human cancer 显示文摘 | Sznol M Chen L | 2013 | Clin Cancer Res2013，19，5： | 1 |
| 2 | Concurrent phase Ⅰ trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity 显示文摘 | Sosman J A Aronson F R Sznol M | 1997 | Clin Cancer Res1997，3，1： | 1 |
| 3 | Antagonist antibodies to PD-I and B7-HI(PD-Ll) in the treatment of advanced human cancer显示文摘 | Sznol M Chen L | 2013 | Clin Cancer Res2013，19，5： | 1 |
| 4 | Molecular markers of response to treatment for melanoma 显示文摘 | Sznol M Cancer J | 2011 | Cancer J2011，17，2： | 1 |
| 5 | Blockade of the B7-H 1/PD-1 pathway for cancer immunotherapy 显示文摘 | FLIES D B SANDLER B J SZNOL M | 2011 | The Yale journal of biology and medicine2011，84，4： | 1 |
| 6 | Survival and long - term follow - up of safety and response in patients (pts) with ad- vanced melanoma (MEL) in a phase I trial of nivolumab ( anti - PD - 1 ; BMS -936558; ONO -4538) 显示文摘 | SZNOL M KLUGER H M HODI F S | 2013 | J Clin Oncol2013，，： | 1 |
| 7 | Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies显示文摘 | Ascierto PA Simeone E Sznol M | | 0，，： | 1 |
| 8 | Use of preferentially rephcating bacteria for the treatment of cancer 显示文摘 | Sznol M Lin SL Bermudes D | 2000 | J Clin invest2000，105，8： | 1 |
| 9 | Survival and long-term follow-up of safety and response in patients (pts) with ad- vanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1;BMS-936558;ONO-4538) 显示文摘 | Sznol M Harriet M Kluger F | 2013 | J Clin Oncol2013，，： | 1 |
| 10 | Advances in the treatment of metastatic melanoma: new im- munomodulatory agents 显示文摘 | Sznol M | 2012 | Semin Oncol2012，39，2： | 1 |
| 11 | Survival, durable tumor remission, and long - term safety in patients with advanced melanoma receiving nivolumab 显示文摘 | TOPALIAN S L SZNOL M MCDERMOTY D F | 2014 | J Clin Oncol2014，32，10： | 1 |
| 12 | Survival,durable tumor remission,and long-term safety in patients with advanced melanoma receiving nivolumab 显示文摘 | TOPALIAN S L SZNOL M MCDERMOTT D F | 2014 | J Clin Oncol2014，32，10： | 1 |
| 13 | Phase 2,multicenter,safety and efficacy study of pidilizumab in patients with metastatic melanoma 显示文摘 | ATKINS M B KUDCHADKAR R R SZNOL M | 2014 | J Clin Oncol2014，，： | 1 |
| 14 | Safety and antitu- mor activity of biweekly MDX - 1106 ( Anti - PD - 1, BMS -936558/0N0 -4538)in patients with advanced refrac- tory malignancies 显示文摘 | Sznol M Powderly JD Smith DC | 2010 | J Clin Oncol2010，28，： | 1 |
| 15 | Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy显示文摘 | Flies DB Sandler BJ Sznol M | 2011 | Yale J Biol Med2011，84，4： | 1 |
| 16 | Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab ( NIVO, anti - PD - 1, BMS - 936558, ONO - 4538 ) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) 显示文摘 | SZNOL M KLUGER H M CALLAHAN M K | 2014 | J Clin Oncol2014，32，18： | 1 |
| 17 | Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy显示文摘 | Flies DB Sandier BJ Sznol M | 2011 | Yale J Biol Med2011，84，4： | 1 |
| 18 | A phase I/II study of CR011-vcM-MAE, an antibody-drug conjugate (ADC) targeting glycoproteinNMB (GPNMB) in patients (pts) with advanced melanoma显示文摘 | Hwu P Sznol M Pavlick A | 2009 | J ClinOncol2009，27，15： | 1 |
| 19 | Survival,durable tumor remission, and long-term safety in patientswith advanced melanoma receiving nivolumab显示文摘 | Topalian SL Sznol M McDermott DF | 2014 | J ClinOncol2014，32，10： | 1 |
| 20 | Survival,durable tumor remission ,and long-term safety in patients with advanced melanoma receiving nivolumab显示文摘 | Topalian SL Sznol M McDermott DF | 2014 | J Clin Oucol2014，32，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员